CHIMERIC ONCOLYTIC HERPESVIRUS THAT STIMULATE AN ANTITUMOR IMMUNE RESPONSE

• Main Authors: ROTH JUSTIN C, CASSADY KEVIN A
• Format: Patent
• Language: Chinese; English
• Published: 14.09.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

A chimeric oncolytic virus is described that includes a herpesvirus having a modified nucleic acid sequence, including a modification of the herpesvirus gamma (1)34.5 gene ([gamma]134.5) or a nucleic acid with at least about 70% homology to the [gamma]134.5 gene that reduces its expression; a second viral nucleic acid sequence encoding a PKR evasion protein that does not cause virulence; and a third nucleic acid sequence encoding a tumor-associated antigen. Methods of using the chimeric oncolytic virus to treat subjects having cancer, or to vaccinate subjects at risk of developing cancer, are also described. 描述的是嵌合溶瘤病毒，其包含：具有修饰的核酸序列的疱疹病毒，所述修饰的核酸序列包括降低其表达的疱疹病毒γ（1）34.5基因（γ134.5），或与γ134.5基因具有至少约70%同源性的核酸的修饰；编码不引起毒力的PKR逃避蛋白的第二病毒核酸序列；以及编码肿瘤相关抗原的第三核酸序列。还描述的是使用嵌合溶瘤病毒来治疗患有癌症的受试者、或给处于发展癌症的风险中的受试者接种疫苗的方法。